The DOI matches its Crossref record; 176 of the 177 references it cites were found in a registry or an index.
From tumour heterogeneity to advances in precision treatment of colorectal cancer
Open accessAbstract
In recent years, the high heterogeneity of colorectal cancer (CRC) has become evident. Hence, biomarkers need to be developed that enable the stratification of patients with CRC into different prognostic subgroups and in relation to response to therapies, according to the distinctive tumour biology. Currently, only RAS-mutation status is used routinely as a negative predictive marker to avoid treatment with anti-EGFR agents in patients with metastatic CRC, and mismatch-repair status can guide the use of adjuvant chemotherapy in patients with early stage colon cancer. Advances in molecular biology over the past decade have enabled a better understanding of the development of CRC, as well as the more-precise use of innovative targeted therapies for this disease, and include three fundamental achievements. First, the availability of large databases to capture and store the genomic landscape of patients with CRC, providing information on the genes that are frequently deregulated in CRC. Second, the possibility of using gene-expression profiling to differentiate the subtypes of CRC into prognostic groups. Third, results from highly sensitive next-generation sequencing analyses have led to an appreciation of the extensive intratumoural heterogeneity of CRC. Herein, we discuss these advances and place them into the clinical context, and present the novel targets and therapeutic opportunities that are on the horizon.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“5-FU/LV is useful in palliative therapy for mCRC, but the development of effective doublet combination therapy regimens, including FOLFOX (folinic acid (leucovorin), 5-FU, oxaliplatin) and FOLFIRI (leucovorin, 5-FU, irinotecan) [10], resulted in significant survival advantages.”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170
Self-citationA human colon cancer cell capable of initiating tumour growth in immunodeficient mice
O'Brien, C. A., Pollett, A. F., Gallinger, S., & Dick, J. E. (2006) · Nature · doi:10.1038/nature05372 · Cited by 4,174
Identification and expansion of human colon-cancer-initiating cells
Ricci‐Vitiani, L., Lombardi, D. G., Pilozzi, E., Biffoni, M., Todaro, M., Peschle, C., & Maria, R. D. (2006) · Nature · doi:10.1038/nature05384 · Cited by 4,001
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Flagged first, then by citations
1 of the 177 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 101–200 of 677
A mouse model for peritoneal metastases of colorectal origin recapitulates patient heterogeneity
Bastiaenen, V. P., Klaver, C. E. L., van der Heijden, M., Nijman, L. E., Lecca, M. C., Tanis, P. J., Lenos, K., & Vermeulen, L. (2020) · Laboratory Investigation · doi:10.1038/s41374-020-0448-x · Cited by 43
Self-citationGmeiner, W. H. (2020) · Cancers · doi:10.3390/cancers12061641 · Cited by 43
Prieur, A., Cappellini, M., Habif, G., Lefranc, M., Mazard, T., Morency, E., Pascussi, J., Flacelière, M., Cahuzac, N., Vire, B., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0533 · Cited by 44
“Currently, only RAS mutation status is used as a negative predictive marker to avoid treatment with anti-EGFR agents in patients withmetastatic colorectal cancer (4).”
BackgroundA Comprehensive Overview of Colon Cancer- A Grim Reaper of the 21st Century
Kumar, R., Harilal, S., Carradori, S., & Mathew, B. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666201026143757 · Cited by 44
Yu, J., Li, S., Xu, Z., Guo, J., Li, X., Wu, Y., Zheng, J., & Sun, X. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01148-1 · Cited by 46
Regulatory miRNAs in Colorectal Carcinogenesis and Metastasis
Guo, Y., Bao, Y., & Yang, W. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040890 · Cited by 41
“In colorectal cancers, miRNAs have shown involvement in, or directly regulating, oncogenic signaling pathways, such as Wnt, Ras, TGF-β, and NF-κB/AKT/STAT3 signaling pathways [2,3,9,10].”
BackgroundFan, Q., & Liu, B. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26548 · Cited by 41
“Colorectal cancer is a heterogeneous disease with molecular complexity.(14,15) The heterogeneity makes conventional clinical predictors such as age, gender, and tumor stage insufficient for a precise survival risk prediction for CRC patients.”
BackgroundRimonabant Kills Colon Cancer Stem Cells without Inducing Toxicity in Normal Colon Organoids
Fiore, D., Ramesh, P., Proto, M., Piscopo, C., Franceschelli, S., Anzelmo, S., Medema, J. P., Bifulco, M., & Gazzerro, P. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00949 · Cited by 41
“It has become clear that CRC is a heterogeneous disease, both at intratumoral and intertumoral level (Punt et al., 2016).”
CT-guided percutaneous radiofrequency ablation for lung metastases from colorectal cancer
Hiyoshi, Y., Miyamoto, Y., Kiyozumi, Y., Sawayama, H., Eto, K., Nagai, Y., Iwatsuki, M., Iwagami, S., Baba, Y., Yoshida, N., et al. (2018) · International Journal of Clinical Oncology · doi:10.1007/s10147-018-1357-5 · Cited by 41
Gong, B., Kao, Y., Zhang, C., Sun, F., Gong, Z., & Chen, J. (2020) · Mediators of Inflammation · doi:10.1155/2020/5934821 · Cited by 41
YAP/TAZ signalling in colorectal cancer: lessons from consensus molecular subtypes
Mouillet-Richard, S., & Laurent-Puig, P. (2020) · Cancers · doi:10.3390/cancers12113160 · Cited by 40
“Over the last decade, it has become apparent that CRC is a heterogeneous disease, and that the diversity of CRC encompasses multiple parameters: anatomical location (distal/proximal), anatomopathological stages (so-called stages I to IV), genomic hallmarks (chromosomal instability, microsatellite instability, hypermet…”
BackgroundZhang, C., Zhai, B.-B., Peng, T., Zhong, Z., Xu, L., Zhang, Q.-Z., Li, L., Yi, L., & Xi, Z. (2017) · Dyes and Pigments · doi:10.1016/j.dyepig.2017.04.043 · Cited by 40
HER2 Amplification and Anti-EGFR Sensitivity in Advanced Colorectal Cancer
Bregni, G., Sciallero, S., & Sobrero, A. F. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.7229 · Cited by 40
Haruki, K., Kosumi, K., Li, P., Arima, K., Väyrynen, J. P., Lau, M. C., Twombly, T. S., Hamada, T., Glickman, J. N., Fujiyoshi, K., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0780-3 · Cited by 39
Bin, J., Nie, S., Tang, Z., Kang, A., Fu, Z., Hu, Y., Liao, Q., Xiong, W., Zhou, Y., Tang, Y., et al. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29880 · Cited by 40
Kwakman, J. J. M., Vink, G. R., Vestjens, J. H. M. J., Beerepoot, L. V., de Groot, J. W., Jansen, R. L. H., Opdam, F. L., Boot, H., Creemers, G. J. M., van Rooijen, J. M., et al. (2017) · International Journal of Clinical Oncology · doi:10.1007/s10147-017-1220-0 · Cited by 40
“Although numerous prognostic parameters have been identified in newly diagnosed mCRC patients [15], limited data are available in heavily pretreated mCRC patients.”
BackgroundSelf-citationMei, Z., Shao, Y. W., Lin, P., Cai, X., Wang, B., Ding, Y., Ma, X., Wu, X., Xia, Y., Zhu, D., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4298-5 · Cited by 39
“Current treatment of unresectable metastatic CRC (mCRC) in advanced stage mainly relies on fluoropyrimidine-based chemotherapies alone or in combination with Bevacizumab according to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines) in Colon Cancer [6, 7].”
MethodJeong, S. Y., Kim, W., Byun, B. H., Kong, C., Song, W. S., Lim, I., Lim, S. M., & Woo, S. (2019) · Contrast Media & Molecular Imaging · doi:10.1155/2019/3515080 · Cited by 40
Zhou, J., Li, S., Han, M., Hu, G., & Cheng, P. (2020) · PubMed Central · Cited by 39
Vafaei, S., Zanjani, L. S., Shams, Z. H., Naseri, M., Fattahi, F., Gheytanchi, E., Alemrajabi, M., Ebrahimi, M., & Madjd, Z. (2020) · Scientific Reports · doi:10.1038/s41598-020-74810-6 · Cited by 39
Fattahi, F., Zanjani, L. S., Shams, Z. H., Kiani, J., Mehrazma, M., Najafi, M., & Madjd, Z. (2021) · Scientific Reports · doi:10.1038/s41598-021-92720-z · Cited by 41
Dong, Y., Yuan, Q., Ren, J., Li, H., Guo, H., Guan, H., Jiang, X., Qi, B., & Li, R. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1090906 · Cited by 38
“02 and immunotherapy are strongly correlated withmetabolic heterogeneity (17, 18).”
Nanoparticles Loaded with Platinum Drugs for Colorectal Cancer Therapy
Buyana, B., Naki, T., Alven, S., & Aderibigbe, B. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911261 · Cited by 39
Noser, A. A., Abdelmonsef, A. H., & Salem, M. M. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.106299 · Cited by 38
Pathobionts in the tumour microbiota predict survival following resection for colorectal cancer
Alexander, J. L., Posma, J. M., Scott, A. J., Poynter, L., Mason, S., Dória, M. L., Herendi, L., Roberts, L., McDonald, J. A. K., Cameron, S. J. S., et al. (2023) · Microbiome · doi:10.1186/s40168-023-01518-w · Cited by 40
Zhang, D., Ni, Q.-Q., Liang, Q.-Y., He, L.-L., Qiu, B.-W., Zhang, L.-J., Mou, T., Le, C., Huang, Y., Li, T., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02806-3 · Cited by 37
“INTRODUCTION Colorectal cancers (CRCs) show high intratumoral genetic heterogeneity [1, 2], which has a major effect on the efficacy of immunotherapy.”
BackgroundResearch Advances of Lipid Nanoparticles in the Treatment of Colorectal Cancer
Zhang, J., Ali, K., & Wang, J. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s466490 · Cited by 38
Sa, K.-D., Zhang, X., Li, X., Gu, Z., Yang, A., Zhang, R., Li, J., & Sun, J. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.05.062 · Cited by 37
Liang, Y., Su, Q., & Wu, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.571655 · Cited by 37
Heidrich, I., Abdalla, T. S. A., Reeh, M., & Pantel, K. (2021) · Cancers · doi:10.3390/cancers13184500 · Cited by 38
“These differences in CRC complicate prognostication and guidance for optimal timing and treatment selection at an individual level [10].”
BackgroundLü, L., Zhang, H., Zhou, Y., Lin, J., Gao, W., Yang, T., Jin, J., Zhang, L., Nagle, D. G., Zhang, W., et al. (2022) · Theranostics · doi:10.7150/thno.71129 · Cited by 36
“The high degree of intratumoral heterogeneity (ITH) of CRC is one of the major factors contributing to immunotherapeutic responses in patients [33].”
BackgroundPersonalised neoantigen‐based therapy in colorectal cancer
Zhu, Y., Li, X., Chen, T., Wang, J., Zhou, Y., Mu, X., Du, Y., Wang, J., Tang, J., & Liu, J. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1461 · Cited by 37
“143 Therefore, for patients with CRC, tumour heterogeneity has become a major challenge in diagnosis and treatment.”
BackgroundHamid, M. A., Pammer, L. M., Oberparleiter, S., Günther, M., Amann, A., Gruber, R., Mair, A., Nocera, F. I., Ormanns, S., Zimmer, K., et al. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00892-y · Cited by 41
Individual Susceptibility Analysis Using Patient-derived Slice Cultures of Colorectal Carcinoma
Sönnichsen, R., Hennig, L., Blaschke, V., Winter, K., Körfer, J., Haehnel, S., Monecke, A., Wittekind, C., Jansen‐Winkeln, B., Thieme, R., et al. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2017.11.002 · Cited by 38
“Even within the same specimen, different morphologic and molecular features are found.(6) We were able to demonstrate that reproducible data regarding tumor proliferation can be obtained in organotypic slice cultures of patient-derived cancer specimens, while considering heterogeneity as an inevitable component of a c…”
BackgroundYang, J., Xu, W. W., Hong, P., Ye, F., Huang, X., Hu, H., Zhang, Q., Yan, X., Li, B., & He, Q. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.02.050 · Cited by 36
Buikhuisen, J. Y., Gomez Barila, P. M., Torang, A., Dekker, D., de Jong, J. H., Cameron, K., Vitale, S., Stassi, G., van Hooff, S. R., Castro, M. A. A., et al. (2021) · Cancers · doi:10.3390/cancers13040801 · Cited by 33
“The existence of these two major classes bears clinical relevance, but their associated mutations or differential activity of cell signalling pathways alone cannot fully explain the distinct prognosis or response to currently used therapies [3].”
BackgroundSelf-citationCiepiela, I., Szczepaniak, M., Ciepiela, P., Hińcza, K., Kopczyński, J., Macek, P., Kubicka, K., Chrapek, M., Tyka, M., Góźdź, S. S., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-55139-w · Cited by 42
“Mutations in the TP53 gene were the most frequently detected in the cohort of 552 cases (Supplemental Tables 6 and 7).”
Zhu, B., Luo, J., Jiang, Y., Yu, L., Liu, M., & Fu, J. (2018) · Cancer Medicine · doi:10.1002/cam4.1663 · Cited by 37
Gockel, I., Jansen‐Winkeln, B., Haase, L., Niebisch, S., Moulla, Y., Lyros, O., Lordick, F., Schierle, K., Wittekind, C., & Thieme, R. (2019) · Tumori Journal · doi:10.1177/0300891619868013 · Cited by 35
Association of autophagy status with amount of Fusobacterium nucleatum in colorectal cancer
Haruki, K., Kosumi, K., Hamada, T., Twombly, T. S., Väyrynen, J. P., Kim, S. A., Masugi, Y., Qian, Z. R., Mima, K., Baba, Y., et al. (2019) · The Journal of Pathology · doi:10.1002/path.5381 · Cited by 38
“Even the best experimental model could not recapitulate the complexity of human tumourmicroenvironment, which is influenced by genetic and epigenetic alterations, environmental exposures, gut microbiota, and host factors [29,30].”
BackgroundYao, Y., Wang, X., Zhou, D., Li, H., Qian, H., Zhang, J., Jiang, L., Wang, B., Lin, Q., & Zhu, X. (2020) · Aging · doi:10.18632/aging.103393 · Cited by 35
“However, the complex mechanism of CRC genesis considerably limits the therapeutic outcomes in advanced cancer [2, 3].”
BackgroundOsumi, H., Vecchione, L., Keilholz, U., Vollbrecht, C., Alig, A. H. S., von Einem, J. C., Stahler, A., Striefler, J. K., Kurreck, A., Kind, A. J., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.05.010 · Cited by 38
Colon Cancer: Epithelial Notch Signaling Recruits Neutrophils to Drive Metastasis
Ruland, J. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.08.010 · Cited by 34
Vafaei, S., Roudi, R., Madjd, Z., Aref, A. R., & Ebrahimi, M. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01389-3 · Cited by 35
Liu, J., Huang, Z., Chen, H., Qin, S., Chen, Y., Jiang, J., Zhang, Z., Luo, M., Ye, Q., Xie, N., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01713-9 · Cited by 37
“improved through adjuvant chemotherapy [42], while only a subset of patients with metastatic disease benefit from systemic treatments [2].”
BackgroundZinc finger protein 384 enhances colorectal cancer metastasis by upregulating MMP2
Yan, Z., Yu, Z., Yang, Y., Zeng, C., Li, P., Tian, H., Tang, X., & Zhang, G. (2022) · Oncology Reports · doi:10.3892/or.2022.8260 · Cited by 33
Vodenková, S., Jirásková, K., Urbanova, M., Kroupa, M., Slyšková, J., Schneiderová, M., Levý, M., Büchler, T., Liška, V., Vodičková, Ľ., et al. (2018) · DNA repair · doi:10.1016/j.dnarep.2018.09.006 · Cited by 33
Prognostic evaluation of resectable colorectal cancer using platelet‑associated indicators
Qian, W., Ge, X., Wu, J., Gong, F., Wu, M., Xu, M., Lian, L., Wang, W., Li, W., & Tao, M. (2019) · Oncology Letters · doi:10.3892/ol.2019.10388 · Cited by 33
“It is widely accepted that surgical resection is the principal therapy option at the early stages of CRC, which is defined as invasion and lymph node metastasis only occurring locally (3).”
BackgroundVafaei, S., Fattahi, F., Ebrahimi, M., Janani, L., Shariftabrizi, A., & Madjd, Z. (2019) · Cancer Management and Research · doi:10.2147/cmar.s219699 · Cited by 33
“There is a need for new methods that are simple, non-invasive, and inexpensive to provide clear clinical evidence and improve early detection or predict a response to treatment.(3,4) Serum biomarkers such as carcinoembryonic antigens (CEAs) and carbohydrate antigen 19-9 (CA19-9) along with multi-target stool DNA tests…”
MethodDu, T., Gao, Q., Zhao, Y., Gao, J., Li, J., Wang, L., Li, P., Wang, Y., Du, L., & Wang, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.651796 · Cited by 33
Goey, K. K. H., Sørbye, H., Glimelius, B. L. G., Adams, R., André, T., Arnold, D., Berlin, J. D., Bodoky, G., de Gramont, A., Díaz‐Rubio, E., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.05.010 · Cited by 34
Self-citationMetabolism-Associated Molecular Classification of Colorectal Cancer
Zhang, M., Wang, H., Peng, R., Xu, F., Wang, F., & Zhao, Q. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.602498 · Cited by 31
“As we were known, CRC is a heterogeneous disease, therefore, more researches should be conducted for precisely understanding the molecular properties of CRC (7).”
BackgroundSi, Z., Yu, L., Jing, H., Wu, L., & Wang, X. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01882-1 · Cited by 32
“Despite remarkable advances, the molecular basis of CRC progression is not fully understood and more effective therapeutic strategies are needed [2].”
BackgroundOligo-Metastatic Cancers: Putative Biomarkers, Emerging Challenges and New Perspectives
Ottaiano, A., Santorsola, M., Circelli, L., Trotta, A. M., Izzo, F., Perri, F., Cascella, M., Sabbatino, F., Granata, V., Correra, M., et al. (2023) · Cancers · doi:10.3390/cancers15061827 · Cited by 32
Strategy to targeting the immune resistance and novel therapy in colorectal cancer
Wang, G., Wang, J., Guan, R., Sun, Y., Shi, F., Zhang, J., Li, Z., Gao, J., & Fu, X. (2018) · Cancer Medicine · doi:10.1002/cam4.1386 · Cited by 33
Farooqı, A. A., Khalid, S., Tahir, F. Z., Sabitaliyevich, U. Y., Yaylım, İ., Attar, R., & Xu, B. (2018) · Food and Chemical Toxicology · doi:10.1016/j.fct.2018.05.024 · Cited by 34
Greenbaum, A. A., Martin, D. R., Bocklage, T. J., Lee, J., Ness, S. A., & Rajput, A. (2019) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2019.02.003 · Cited by 30
Wang, Y., Shi, J., Zhou, Y., Liu, T., Li, J., Hong, F., Zhang, K., & Liu, N. (2019) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201900017 · Cited by 31
Cui, K., Yao, S., Zhang, H., Zhou, M., Liu, B., Cao, Y., Fei, B., Huang, S., & Huang, Z. (2021) · Oncogene · doi:10.1038/s41388-021-01677-w · Cited by 32
“CRC is a solid cancer type with a complex and heterogeneous tumor microenvironment (TME) [2].”
BackgroundKucherov, F. A., Egorova, K. S., Posvyatenko, A. V., Eremin, D. B., & Ananikov, V. P. (2017) · Analytical Chemistry · doi:10.1021/acs.analchem.7b03568 · Cited by 31
Pharmacogenomics, biomarker network, and allele frequencies in colorectal cancer
López‐Cortés, A., Paz‐y‐Miño, C., Guerrero, S. X., Jaramillo-Koupermann, G., Cáceres, Á. L., Intriago-Baldeón, D. P., García-Cárdenas, J. M., Guevara‐Ramírez, P., Armendáriz‐Castillo, I., Leone, P., et al. (2019) · The Pharmacogenomics Journal · doi:10.1038/s41397-019-0102-4 · Cited by 29
Forster, S., & Radpour, R. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.569017 · Cited by 31
Nguyen, H.-G., Blank, A., Dawson, H., Lugli, A., & Zlobec, I. (2021) · Scientific Reports · doi:10.1038/s41598-021-81352-y · Cited by 29
Tumor Microenvironment in Metastatic Colorectal Cancer: The Arbitrator in Patients’ Outcome
Galindo-Pumariño, C., Collado, M., Herrera, M., & Peña, C. (2021) · Cancers · doi:10.3390/cancers13051130 · Cited by 31
“Currently, only rat sarcoma oncogene (RAS) mutation status is routinely used as a negative predictive marker to avoid treatment with anti-EGFR agents in patients with mCRC; and mismatch repair (MMR) status may guide the use of immune checkpoint inhibitors [36].”
BackgroundJung, H. R., Oh, Y., Na, D., Min, S., Kang, J., Jang, D., Shin, S., Kim, J., Lee, S. E., Jeong, E. M., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01777-7 · Cited by 29
“are the only clinically approved targeted drugs for CRC [3].”
BackgroundLiu, L., Liu, T., Tao, W., Liao, N., Yan, Q., Li, L., Tan, J., Shen, W., Cheng, H., & Sun, D. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154007 · Cited by 30
Rokavec, M., Bouznad, N., & Hermeking, H. (2019) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2019.02.003 · Cited by 29
Hypoxia‐Responsive Platinum Supernanoparticles for Urinary Microfluidic Monitoring of Tumors
Xu, Q. H., Pan, Y., Liu, X., Gao, Y., Luan, X., Zeng, F., Zhou, D., Long, W., Wang, Y., & Song, Y. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202114239 · Cited by 29
Gorzo, A., Galoș, D., Volovăț, S. R., Lungulescu, C. V., Burz, C. C., & Sur, D. G. (2022) · Life · doi:10.3390/life12020229 · Cited by 30
“In selected patients, surgical resection of metastases is advisable either upfront or following downsizing systemic treatment [14,15].”
BackgroundInfluentialHu, L.-P., Huang, W., Wang, X., Xu, C., Qin, W., Li, D., Tian, G.-A., Li, Q., Zhou, Y.-Q., Chen, S.-Y., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.06.015 · Cited by 31
ATF2 loss promotes tumor invasion in colorectal cancer cells via upregulation of cancer driver TROP2
Huebner, K., Erlenbach‐Wuensch, K., Procházka, J., Sheraj, I., Hampel, C., Mrázková, B., Michalčíková, T., Turečková, J., Iatsiuk, V., Weissmann, A., et al. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04445-5 · Cited by 29
“Intratumoral heterogeneity (ITH) exists and arises among cancer cells within the same tumor as a result of (epi-) genetic changes, environmental differences, and cellular plasticity [4].”
BackgroundFu, X., Ying, J., Liu, Y., Fang, W. J., Han, W., Hu, H., Zhang, S., & Yuan, Y. (2022) · Cancer Science · doi:10.1111/cas.15660 · Cited by 30
Finetti, F., Paradisi, L., Bernardi, C., Pannini, M., & Trabalzini, L. (2023) · Cancers · doi:10.3390/cancers15082374 · Cited by 30
“EGFR overexpression is an unfavorable prognostic marker in lung cancer [104], squamous cell carcinoma (SCC) [105], colorectal cancer [106,107], and others.”
BackgroundNon-Coding RNAs as Predictive Biomarkers to Current Treatment in Metastatic Colorectal Cancer
Garajová, I., Ferracin, M., Porcellini, E., Palloni, A., Abbati, F., Biasco, G., & Brandi, G. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071547 · Cited by 28
“This is especially due to the incorporation of monoclonal antibodies against vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) in the treatment of metastatic CRC [2].”
BackgroundInvestigation of the role and mechanism of ARHGAP5-mediated colorectal cancer metastasis
Tian, T., Chen, Z., Zheng, Z., Liu, Y., Zhao, Q., Liu, Y., Qiu, H., Long, Q., Chen, M., Li, L., et al. (2020) · Theranostics · doi:10.7150/thno.43427 · Cited by 30
“Progress has been made in the treatment of metastatic CRC in the past several decades due to the development of targeted drugs and immunotherapy [28].”
BackgroundThe Impact of Cancer Stem Cells in Colorectal Cancer
Radu, P., Zurzu, M., Tigora, A., Paic, V., Bratucu, M., Garofil, D., Surlin, V., Munteanu, A. C., Coman, I. S., Popa, F., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084140 · Cited by 30
Comparison of beta diversity measures in clustering the high-dimensional microbial data
Chen, B., He, X., Pan, B., Zou, X., & You, N. (2021) · PLoS ONE · doi:10.1371/journal.pone.0246893 · Cited by 28
Huang, W., Lin, C., Chen, C., Chang, S., Chang, H., & Lee, K. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26898 · Cited by 28
“Colorectal cancer (CRC), one of the most prevalent and deadly cancer types worldwide, remains the leading cause of cancer mortality with a high disease incidence.(1) Although early diagnosis of CRC has markedly improved survival in recent years, the 5-year survival rate is still very low in advanced CRC patients with…”
BackgroundGu, L., Liu, Y., Jiang, C., Sun, L., & Zhou, H. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105087 · Cited by 28
TOX Acts as a Tumor Suppressor by Inhibiting mTOR Signaling in Colorectal Cancer
Yang, M., Huang, Q., Li, C., Jiang, Z., Sun, J. P., Wang, Z., Liang, R., Li, D., Li, B., & Zhao, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.647540 · Cited by 29
“Surgical treatment of early-stage CRC improves prognosis, but the treatment of patients with mid-advanced CRC remains a challenging clinical research focus (3).”
BackgroundHu, S., Ruan, C., Xu, Y., Teng, X., Fan, R., Jiang, T., Cao, M., & Song, J. (2021) · Experimental Biology and Medicine · doi:10.1177/15353702211065010 · Cited by 30
Zhang, H., Du, Y., Wang, Z., Lou, R., Wu, J., & Feng, J. (2019) · Biochemistry Research International · doi:10.1155/2019/6469420 · Cited by 29
“Treatment according to the distinctive tumor biology is an effective means to reduce the mortality of patients with CRC, as well as the detection of biomarkers that enable the stratification of patients with CRC into different prognostic subgroups and in relation therapeutic response [5].”
BackgroundDai, D., Wang, Y., Zhu, L., Jin, H., & Wang, X. (2020) · PeerJ · doi:10.7717/peerj.9149 · Cited by 27
Signatures of co-deregulated genes and their transcriptional regulators in colorectal cancer
Mastrogamvraki, N., & Zaravinos, A. (2020) · npj Systems Biology and Applications · doi:10.1038/s41540-020-00144-8 · Cited by 28
Tsiakanikas, P., Adamopoulos, P. G., Tsirba, D., Artemaki, P. I., Papadopoulos, I. N., Kontos, C. K., & Scorilas, A. (2022) · Biomedicines · doi:10.3390/biomedicines10051120 · Cited by 27
“However, sporadic CRC is characterized by a genomic complexity and heterogeneity, which can directly affect the clinical behavior of the tumor [4].”
BackgroundWu, Y., Mao, A., Wang, H., Fang, G., Zhou, J., He, X., Cai, S., & Wang, L. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.31956 · Cited by 27
Wang, N., Cao, Y., Si, C., Shao, P., Su, G., Wang, X., Bao, J., & Liu, Y. (2022) · Cancers · doi:10.3390/cancers14205160 · Cited by 29
“The findings from a study suggested that although HER2 amplification may be absent in tumors not treated with anti-EGFR drugs, it is elevated after exposure to these agents [91].”
BackgroundLiu, L., Yan, X., Wu, D., Yang, Y., Li, M., Yang, S., Yang, W., Shan, Z., Gao, Y., & Jin, Z. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0827-y · Cited by 28
Lu, X., Wu, X., Jing, L., Tao, L., Zhang, Y., Huang, R., Zhang, G., & Ren, J. (2020) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2020/4517483 · Cited by 27
“CRC is a heterogeneous and molecularly complex disease [21].”
BackgroundShields, N. J., Peyroux, E. M., Ferguson, A. L., Steain, M. C., Neumann, S., & Young, S. L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1152035 · Cited by 31
“Mounting evidence illustrates that human tumours and the composition of their immune infiltrates are highly heterogeneous (3, 4) and that effective anti-tumour immunity can be hindered by numerous immune evasion and suppression mechanisms (5).”
BackgroundConradi, L., Spitzner, M., Metzger, A.-L. C., Kisly, M., Middel, P., Bohnenberger, H., Gaedcke, J., Ghadimi, M. B., Liersch, T., Rüschoff, J., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-6051-0 · Cited by 27
Laoukili, J., van Schelven, S., Küçükköse, E., Verheem, A., Goey, K. K. H., Koopman, M., Rinkes, I. H. M. B., & Kranenburg, O. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111728 · Cited by 28
Self-citationGoel, G. (2018) · Cancer Management and Research · doi:10.2147/cmar.s162967 · Cited by 26
“Intratumoral heterogeneity relates to genetic heterogeneity, functional heterogeneity, and nongenetic (epigenetic) heterogeneity.(128) Genetic heterogeneity can be attributed to varying number of cancer clones depending upon the mutation rates and differences in the ability of these clones to metastasize or/and their…”
BackgroundUpregulated NLGN1 predicts poor survival in colorectal cancer
Yu, Q., Wang, X., Yang, Y., Chi, P., Huang, J., Qiu, S., Zheng, X. M., & Chen, X. (2021) · BMC Cancer · doi:10.1186/s12885-021-08621-x · Cited by 26
Okamoto, T., Natsume, Y., Doi, M., Nosato, H., Iwaki, T., Yamanaka, H., Yamamoto, M., Kawachi, H., Noda, T., Nagayama, S., et al. (2022) · Cancer Science · doi:10.1111/cas.15396 · Cited by 25
Improved potency of F10 relative to 5-fluorouracil in colorectal cancer cells with p53 mutations
Dominijanni, A. J., & Gmeiner, W. H. (2018) · Cancer Drug Resistance · doi:10.20517/cdr.2018.01 · Cited by 24
“Ras mutations and DNA mismatch repair (MMR) status are the predominant biomarkers used to direct clinical decisions[2].”
BackgroundInfluentialWielandt, A. M., Hurtado, C., Mauricio Moreno, C., Villarroel, C., Castro, M., Estay, M., Simian, D., Martínez, M., Vial, M. T., Kronberg, U., et al. (2020) · Tumor Biology · doi:10.1177/1010428320938492 · Cited by 24
“83 Yes 32 (36) 5 (33) 37 Lymphovascular invasion No 58 (66) 7 (47) 65 0.”
InfluentialZhu, S., Wu, Q., Zhang, B., Wei, H., Li, B., Shi, W., Fang, M., Zhu, S., Wang, L., Zhou, Y. L., et al. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106757 · Cited by 24
Tomasini, P. P., Guecheva, T. N., Leguisamo, N. M., Péricart, S., Brunac, A., Hoffmann, J., & Saffi, J. (2021) · Cancers · doi:10.3390/cancers13133130 · Cited by 25
Liu, H., Ye, Z., Yang, T., Xie, H., Duan, T., Li, M., Wu, M., & Song, B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.724464 · Cited by 23
“Medical imaging can capture information about the heterogeneity of the entire tumor noninvasively and could well predict tumor subtypes and the sensitivity of immunotherapy (11, 12).”
Background
Metadata
- Authors
- Punt, C. J. A., Koopman, M., & Vermeulen, L.
- Affiliations
- Amsterdam UMC Location University of Amsterdam (NL)
- University Medical Center Utrecht (NL)
- Corresponding author
- Punt, Cornelis J. A.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2016-12-06
- Volume
- 14
- Issue
- 4
- Pages
- 235-246
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W2560375214
- Cited by
- 654
- References
- 177
- Citations by year
- 2026: 38 · 2025: 41 · 2024: 87 · 2023: 79 · 2022: 88 · 2021: 96 · 2020: 83 · 2019: 57 · 2018: 56 · 2017: 28
- FWCI
- 4.73
- Type
- journal article
- Language
- en
- Open access
- green
- pure.amsterdamumc.nl
- Licence
- Locations
- Nature Reviews Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Utrecht University Repository (Utrecht University) (submittedVersion)
- Funders
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
- Maag Lever Darm Stichting (MLDS-CDG 14-03)
- H2020 European Research Council (638193)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Keywords
- colorectal cancer, intratumoral heterogeneity, precision medicine, targeted therapy, gene expression profiling, tumor subtypes, prognostic factors, predictive biomarkers, RAS mutations, DNA mismatch repair, anti-EGFR therapy, adjuvant chemotherapy, next-generation sequencing
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Forecasting, Humans, Immunotherapy, Neoplasm Metastasis, Neoplasm Proteins, Neoplasm Staging, Prognosis, Quality of Health Care, Colorectal Neoplasms, Treatment Outcome, Genetic Heterogeneity, Therapies, Investigational, Proto-Oncogene Proteins B-raf, DNA Mismatch Repair, Early Detection of Cancer, Precision Medicine, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
